

## Special Issue

# Strategies for the Discovery of Antivirals Against Respiratory RNA Viruses 2026

### Message from the Guest Editors

Respiratory RNA viruses continue to pose significant threats to global public health, as evidenced by recent outbreaks and pandemics. This Special Issue aims to highlight innovative strategies and recent advances in the discovery and development of antiviral agents targeting respiratory RNA viruses. Topics of interest include, but are not limited to, structure-based drug design, high-throughput screening, repurposing of existing drugs, and the application of nanotechnology in antiviral development, including the design of nanomaterials for direct virion inhibition, targeted drug delivery, and as novel antiviral platforms. We also welcome contributions on novel therapeutic platforms and the evaluation of antiviral efficacy in preclinical and clinical settings. We invite original research articles, reviews, and perspectives that contribute to the understanding and advancement of antiviral discovery against pathogens such as influenza, RSV, SARS-CoV-2, and other emerging respiratory RNA viruses.

### Guest Editors

Dr. Yuanwei Pan

Institute of Chemical Biology, Shenzhen Bay Laboratory, Shenzhen 518132, China

Dr. Badri Parshad

Wellman Center for Photomedicine, Harvard Medical School, Massachusetts General Hospital, Charlestown, MA 02129, USA

Dr. Xinyi Liu

Beijing Institute of Radiation Medicine, Beijing, China

### Deadline for manuscript submissions

31 July 2026



## Viruses

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.5  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/si/263149](https://mdpi.com/si/263149)

*Viruses*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[viruses@mdpi.com](mailto:viruses@mdpi.com)

[mdpi.com/journal/  
viruses](https://mdpi.com/journal/viruses)





# Viruses

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.5  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/journal/  
viruses](https://mdpi.com/journal/viruses)



## About the Journal

### Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Viruses* (ISSN 1999-4915). *Viruses* is published in open access format—research articles, reviews and other content are released on the internet immediately after acceptance. The scientific community and the general public have unlimited free access to the content as soon as it is published. As an open access journal, *Viruses* is supported by the authors or their institutes by payment of article processing charges (APC) for accepted papers. We would be pleased to welcome you as one of our authors.

---

### Editor-in-Chief

Dr. Eric O. Freed

HIV Dynamics and Replication Program, Center for Cancer Research,  
National Cancer Institute, Frederick, MD 21702-1201, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

#### Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Virology/Infectious Diseases)

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.2 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the second half of 2025).